Fixed-duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study
Hemasphere. 2026 Nov 17;10(11):e70531. doi: 10.1002/hem3.70531. eCollection 2026 Nov.
ABSTRACT
More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T-cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies. Overall, 61 patients were enrolled at the recommended Phase 2 dose of glofitamab (target dose, 30 mg). The overall response rate was 85.2% (95% confidence interval [CI] 73.8-93.0), and complete response (CR) rate was 77.0% (95% CI 64.5-86.9). After a median follow-up of 29.3 months, the median duration of CR was 40.2 months (95% CI 20.0-not estimable [NE]). Median progression-free survival was 21.4 months (95% CI 11.4-NE) and the 24-month progression-free survival rate was 49.0%. The most common adverse event was cytokine release syndrome (62.3%; all Grade ≤2). Immune effector cell-associated neurotoxicity syndrome rates were low (6.5%; Grade ≤2, 4.9%; Grade 3, 1.6%). Patients had high rates of undetectable minimal residual disease at their first tumor assessment (Cycle 3) (76.3%), which lasted beyond the end-of-treatment (EOT). Immuno-recovery occurred 12-18 months after EOT in patients with ongoing remission, and T-cell count was not impacted by glofitamab treatment. Fixed-duration glofitamab monotherapy induces durable responses with manageable safety. Glofitamab represents an accessible off-the-shelf therapy for patients with R/R FL, including those with high-risk disease, and an important combination partner for the treatment of R/R FL. ClinicalTrials.gov identifier: NCT03075696.
PMID:43048280 | PMC:PMC13776797 | DOI:10.1002/hem3.70531

